Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ASPIRIN versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ASPIRIN versus METHADOSE.
HYDROCODONE BITARTRATE AND ASPIRIN vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
One to two tablets (hydrocodone bitartrate 5-10 mg / aspirin 500 mg) orally every 4-6 hours as needed for pain; maximum daily dose: 8 tablets (hydrocodone 40 mg, aspirin 4000 mg).
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Hydrocodone: terminal elimination half-life of approximately 3.8-4.5 hours (range 3.3-4.4 hours in adults) in healthy individuals; prolonged in hepatic impairment and elderly. Aspirin: 15-20 minutes for parent drug; salicylate half-life is dose-dependent (2-3 hours at low doses, up to 15-30 hours at anti-inflammatory doses).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Hydrocodone: primarily renal (up to 60% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); <10% biliary/fecal. Aspirin: renal excretion of salicylate and its conjugates (salicyluric acid, salicyl phenolic glucuronide, etc.); dose-dependent elimination kinetics.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist